Advertisement

Trends in acute myocardial infarction prognosis and treatment in Southwestern France between 1985 and 1990 (The MONICA project-Toulouse)

  • Jean Ferrie´res
    Correspondence
    Address for reprints: Jean Ferrie´res, MD, MSc, Department of Cardiology, CHU Purpan, 31059 Toulouse Cedex,France.
    Affiliations
    From the Department of Cardiology, Purpan Hospital, Toulouse University School of Medicine, Toulouse, France

    From the Department of Cardiology, Purpan Hospital, Toulouse University School of Medicine, Toulouse, France
    Search for articles by this author
  • Jean-Pierre Cambou
    Affiliations
    From the Department of Cardiology, Purpan Hospital, Toulouse University School of Medicine, Toulouse, France

    From the INSERM 326, ORSMIP, School of Public Health and Community Medicine, Toulouse University School of Medicine, Toulouse, France
    Search for articles by this author
  • Jean-Bernard Ruidavets
    Affiliations
    From the Department of Cardiology, Purpan Hospital, Toulouse University School of Medicine, Toulouse, France

    From the INSERM 326, ORSMIP, School of Public Health and Community Medicine, Toulouse University School of Medicine, Toulouse, France
    Search for articles by this author
  • Jacques Pous
    Affiliations
    From the Department of Cardiology, Purpan Hospital, Toulouse University School of Medicine, Toulouse, France

    From the INSERM 326, ORSMIP, School of Public Health and Community Medicine, Toulouse University School of Medicine, Toulouse, France
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Since 1984, the Multinational Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA project) has studied progress in acute coronary artery disease (CAD) in defined geographic areas. This study, based in a French MONICA center in Southwestern France, assessed acute myocardial infarction (AMI) frequency, prognosis, and treatment between 1985 and 1990. The age-standardized AMI attack rate showed a slight decrease in men (218.3 of 100,000 in 1985 and 200.1 of 100,000 in 1990, p < 0.05). In men, the AMI age-standardized 28-day case fatality rate decreased from 38% in 1985 to 27% in 1990 (p < 0.001), with a dramatic reduction in the age-standardized in-hospital case fatality rate (21% in 1985 and 11% in 1990, p < 0.001). Furthermore, the in-hospital 28-day case fatality decreased exclusively in male patients with a history of CAD (33% in 1986 and 19% in 1990, p < 0.01). AMI treatment improved between 1986 and 1990 with increased use of antiplatelets (40.7% in 1986, 73.6% in 1989, and 84.8% in 1990, p < 0.001), β-blockers (29.5% in 1986, 45.7% in 1989, and 57.7% in 1990, p < 0.001), and thrombolytic therapy (23.6% in 1986, 45.3% in 1989, and 39.5% in 1990, p < 0.001). Invasive cardiology technique utilization increased dramatically between 1986 and 1990 with the generalized use of coronary angiography (68.2% in 1986, 89.3% in 1989, and 87.3% in 1990, p < 0.001) and percutaneous transluminal coronary angioplasty (17.7% in 1986, 49.6% in 1989, and 55.3% in 1990, p < 0.001). French data recorded during the MONICA project showed improvements in the prognosis of patients hospitalized for AMI and in the use of effective therapies. These results suggest that physicians respond quickly to newly published clinical trials.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      Reference

        • AHA Medical/Scientific Statement
        ACC/AHA guidelines for the early management of patients with acute myocardial infarction.
        Circulation. 1990; 82: 664-707
        • Lamas GA
        • Pfeffer MA
        • Hamim P
        • Wertheimer J
        • Rouleau JL
        • Braunwald E
        Do the results of randomized clinical trials of cardiovascular drugs influence medical practice?.
        N Engl J Med. 1992; 327: 241-247
        • Tunstall-Pedoe H
        • Kuulasmaa K
        • Amouyel P
        • Arveiler D
        • Rajakangas AM
        • Pajak A
        Myocardial infarction and coronary deaths in the World Health Organization MONICA project. Registration procedures, events rates and case-fatality rates in 38 populations from 21 countries in four continents.
        Circulation. 1994; 90: 583-612
        • Douste-Blazy Ph
        • Ruidavets JB
        • Arveiler D
        • Bingham A
        • Camare´ R
        • Schaffer P
        • Aby MA
        • Richard JL
        Comparison of cardiovascular risk factor levels in two French populations: Haute-Garonne (Toulouse) and Bas-Rhin (Strasbourg).
        Acta Med Scand. 1988; 728: 137-143
        • Doll R
        Comparison between registries age-standardized rates.
        in: Waterhouse J Muir CS Correa P Powell J Cancer Incidence in Five Continents. IARC, Lyon1976: 453-459
        • Cortina A
        • Ambrose JA
        • Prieto-Granada J
        • Moris C
        • Simarro E
        • Holt J
        • Fuster V
        Left ventricular function after myocardial infarction: clinical and angiographic correlations.
        J Am Coll Cardiol. 1985; 5: 619-624
        • Matsuda Y
        • Ogawa H
        • Moritani K
        • Matsuda M
        • Naito H
        • Matsuzaki M
        • Ikee Y
        • Kusukawa R
        Effects of the presence or absence of preceding angina pectoris on left ventricular function after acute myocardial infarction.
        Am Heart J. 1984; 108: 955-958
        • Muller DW
        • Topol EJ
        • Califf RM
        • Sigmon KN
        • Gorman L
        • George BS
        • Kereiakes DJ
        • Lee KL
        • Ellis SG
        Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarction.
        Am Heart J. 1990; 119: 224-231
        • Barbash GI
        • White HD
        • Modan M
        • Van de Werf F
        Antecedent angina pectoris predicts worse outcome after myocardial infarction in patients receiving thrombolytic therapy: experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
        J Am Coll Cardiol. 1992; 20: 36-41
        • Mueller HS
        • Cohen LS
        • Braunwald E
        • Forman S
        • Feit F
        • Ross A
        • Schweiger M
        • Cabin H
        • Davison R
        • Miller D
        • Solomon R
        • Knatterud G
        Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II.
        Circulation. 1992; 85: 1254-1264
        • Terrin ML
        • Williams DO
        • Kleiman NS
        • Willerson J
        • Mueller HS
        • Desvigne-Nickens P
        • Forman SA
        • Knatterud GL
        • Braunwald E
        Two- and three-year results of the Thrombolysis in Myocardial Infarction (TIMI) phase II clinical trial.
        J Am Coll Cardiol. 1993; 22: 1763-1772
        • ISIS-2 (Second International Study of Infarct Survival) Collaborative Group
        Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.
        Lancet. 1988; 2: 349-360
        • Yusuf S
        • Peto R
        • Lewis J
        • Collins R
        • Sleight P
        Beta blockade during and after myocardial infarction: an overview of the randomized trials.
        Prog Cardiovasc Dis. 1985; 27: 335-371
        • AIMS Trial Study Group
        Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial.
        Lancet. 1988; 1: 545-549
        • Gruppo Italiano per lo Studio della Streptochinasi Nell'Infarto Miocardico (GISSI)
        Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study.
        Lancet. 1987; 2: 871-874
        • Wilcox RG
        • Olsson CG
        • Skene AM
        • Von Der Lippe G
        • Jensen G
        • Hampton JR
        Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET).
        Lancet. 1988; 2: 525-530
        • Gibson RS
        • Boden WE
        • Theroux P
        • Srauss MD
        • Pratt CM
        • Gheorghiade M
        • Capone RJ
        • Crawford MH
        • Schlant RC
        • Kleiger RE
        Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction: results of a double-blind, randomized, multicenter trial.
        N Engl J Med. 1986; 315: 423-429
        • The Danish Study Group on Verapamil in Myocardial Infarction
        Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II-DAVIT II).
        Am J Cardiol. 1990; 66: 779-785
        • Mark DB
        • Naylor CD
        • Hlatky MA
        • Califf RM
        • Topol EJ
        • Granger CB
        • Knight JD
        • Nelson CL
        • Lee KL
        • Clapp-Channing NE
        • Sutherland W
        • Pilote L
        • Armstrong PW
        Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States.
        N Engl J Med. 1994; 331: 1130-1135